Therapeutic Targeting of PARP Expression and Glycolysis Rate-Limiting Enzymes in Breast Cancer Patients.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2025-02-01 DOI:10.31557/APJCP.2025.26.2.611

Shams Firas Adnan, Zainab N Najim Al-Abady

{"title":"Therapeutic Targeting of PARP Expression and Glycolysis Rate-Limiting Enzymes in Breast Cancer Patients.","authors":"Shams Firas Adnan, Zainab N Najim Al-Abady","doi":"10.31557/APJCP.2025.26.2.611","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer is a heterogeneous disease characterized by diverse biochemical, histological, and clinical features. PARP1 and glycolysis rate-limiting enzymes play critical roles in cancer progression, making them promising therapeutic targets.Aim: This study aimed to evaluate the expression levels of PARP1 and key glycolytic enzymes (HK, PFK, and PK) in breast cancer patients and assess their potential as therapeutic indicators.Materials and methods: A total of 120 participants (60 breast cancer patients and 60 healthy controls) were included in the study. Blood samples were collected to measure PARP1 expression and the levels of glycolytic enzymes using ELISA. Statistical analyses were performed to compare the two groups.Results: PARP1 expression and glycolytic enzyme levels (HK, PFK, and PK) were significantly higher in breast cancer patients compared to healthy controls (p < 0.0001).Conclusion: The overexpression of PARP1 and key glycolytic enzymes indicates their involvement in breast cancer progression and underscores their potential as therapeutic targets and biomarkers.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 2","pages":"611-617"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.2.611","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer is a heterogeneous disease characterized by diverse biochemical, histological, and clinical features. PARP1 and glycolysis rate-limiting enzymes play critical roles in cancer progression, making them promising therapeutic targets.

Aim: This study aimed to evaluate the expression levels of PARP1 and key glycolytic enzymes (HK, PFK, and PK) in breast cancer patients and assess their potential as therapeutic indicators.

Materials and methods: A total of 120 participants (60 breast cancer patients and 60 healthy controls) were included in the study. Blood samples were collected to measure PARP1 expression and the levels of glycolytic enzymes using ELISA. Statistical analyses were performed to compare the two groups.

Results: PARP1 expression and glycolytic enzyme levels (HK, PFK, and PK) were significantly higher in breast cancer patients compared to healthy controls (p < 0.0001).

Conclusion: The overexpression of PARP1 and key glycolytic enzymes indicates their involvement in breast cancer progression and underscores their potential as therapeutic targets and biomarkers.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.